Abstract
The sulfonamides constitute an important class of drugs, which display a variety of activities including antibacterial, anticarbonic anhydrase, diuretic, hypoglycemic and antithyroid effectiveness. A number of sulfonamides have been reported to be potent anticancer agents, which interact with a wide range of different cellular targets. Among these interesting sulfonamides, the diaryl or heterocyclic sulfonamides have recently emerged as an important class of antimitotic agents against different types of cancer, including multidrug resistant tumors. This review summarizes the recent advances of the diaryl or heterocyclic sulfonamides as novel antimitotic agents.
Keywords: Antimitotic Agents, Heterocyclic Sulfonamides, anticarbonic anhydrase, hypoglycemic, potent anticancer agents, tumor cell, structure-activity relationships (SAR)
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Diaryl or Heterocyclic Sulfonamides as Antimitotic Agents
Volume: 8 Issue: 7
Author(s): Laixing Hu, Zhuo-rong Li, Jian-dong Jiang and David W. Boykin
Affiliation:
Keywords: Antimitotic Agents, Heterocyclic Sulfonamides, anticarbonic anhydrase, hypoglycemic, potent anticancer agents, tumor cell, structure-activity relationships (SAR)
Abstract: The sulfonamides constitute an important class of drugs, which display a variety of activities including antibacterial, anticarbonic anhydrase, diuretic, hypoglycemic and antithyroid effectiveness. A number of sulfonamides have been reported to be potent anticancer agents, which interact with a wide range of different cellular targets. Among these interesting sulfonamides, the diaryl or heterocyclic sulfonamides have recently emerged as an important class of antimitotic agents against different types of cancer, including multidrug resistant tumors. This review summarizes the recent advances of the diaryl or heterocyclic sulfonamides as novel antimitotic agents.
Export Options
About this article
Cite this article as:
Hu Laixing, Li Zhuo-rong, Jiang Jian-dong and Boykin W. David, Novel Diaryl or Heterocyclic Sulfonamides as Antimitotic Agents, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/187152008785914806
DOI https://dx.doi.org/10.2174/187152008785914806 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CJK-7, a Novel Flavonoid from Paulownia tomentosa Triggers Cell Death Cascades in HCT-116 Human Colon Carcinoma Cells via Redox Signaling
Anti-Cancer Agents in Medicinal Chemistry Screening of Antihypertensive Drugs for Osteoclastic Acid Secretion and Bone Resorption by Acridine Orange
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Multidimensional Integration Analysis of Autophagy-related Modules in Colorectal Cancer
Letters in Organic Chemistry Advanced Carbon-based Nanoplatforms Combining Drug Delivery and Thermal Therapy for Cancer Treatment
Current Pharmaceutical Design N-Heterocyclic Dronic Acids: Applications and Synthesis
Mini-Reviews in Medicinal Chemistry Effects of Propolis and Caffeic Acid Phenethyl Ester (CAPE) on Breast Cancer Cells
Current Pharmacogenomics and Personalized Medicine The Pathophysiological Role of PEDF in Bone Diseases
Current Molecular Medicine Discovery of Allosteric Inhibitors of Kinesin Spindle Protein (KSP) for the Treatment of Taxane-Refractory Cancer: MK-0731 and Analogs
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomics: Dont Forget the Children
Current Pharmacogenomics and Personalized Medicine Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets A Review on Targeting Nanoparticles for Breast Cancer
Current Pharmaceutical Biotechnology EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research The Protective Effect of Jatrorrhizine Against Oxidative Stress in Primary Rat Cortical Neurons
CNS & Neurological Disorders - Drug Targets Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Disseminated Intravascular Coagulation in Leukemia and Sepsis
Vascular Disease Prevention (Discontinued) Aptamers as Therapeutics in Cardiovascular Diseases
Current Medicinal Chemistry ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis
Current Bioactive Compounds Beneficial Effect of Peptides from Microalgae on Anticancer
Current Protein & Peptide Science Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design